See more : 4basebio PLC (4BB.L) Income Statement Analysis – Financial Results
Complete financial analysis of GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GlaxoSmithKline Pharmaceuticals Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Textainer Group Holdings Limited (3T70.F) Income Statement Analysis – Financial Results
- Oryx International Growth Fund Limited (OIG.L) Income Statement Analysis – Financial Results
- NEXTAGE Co., Ltd. (3186.T) Income Statement Analysis – Financial Results
- Fuji Furukawa Engineering & Construction Co.Ltd. (1775.T) Income Statement Analysis – Financial Results
- Shanta Gold Limited (SHG.L) Income Statement Analysis – Financial Results
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.54B | 32.52B | 32.78B | 31.99B | 32.24B | 31.28B | 28.71B | 29.08B | 27.64B | 26.38B | 25.55B | 26.54B | 23.78B | 21.51B | 19.08B | 16.93B | 16.08B | 15.82B | 15.19B | 14.10B |
| Cost of Revenue | 14.20B | 12.85B | 14.50B | 13.95B | 13.98B | 14.45B | 13.28B | 14.82B | 13.33B | 12.26B | 12.29B | 11.57B | 9.19B | 7.88B | 7.02B | 6.56B | 6.37B | 6.31B | 6.39B | 6.04B |
| Gross Profit | 20.34B | 19.67B | 18.28B | 18.04B | 18.27B | 16.84B | 15.44B | 14.27B | 14.30B | 14.13B | 13.25B | 14.97B | 14.59B | 13.63B | 12.06B | 10.38B | 9.72B | 9.51B | 8.80B | 8.06B |
| Gross Profit Ratio | 58.89% | 60.49% | 55.78% | 56.40% | 56.66% | 53.82% | 53.76% | 49.05% | 51.75% | 53.55% | 51.88% | 56.41% | 61.35% | 63.36% | 63.19% | 61.27% | 60.41% | 60.08% | 57.92% | 57.19% |
| Research & Development | 25.44M | 19.10M | 18.29M | 18.07M | 21.80M | 23.27M | 22.52M | 18.96M | 19.96M | 17.55M | 26.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 486.29M | 291.87M | 425.92M | 184.70M | 170.48M | 277.32M | 368.75M | 55.75M | 65.70M | 4.13B | 56.88M | 41.43M | 6.93B | 6.04B | 5.31B | 4.42B | 4.16B | 4.60B | 4.37B | 4.10B |
| Selling & Marketing | 1.80B | 1.66B | 1.84B | 1.72B | 2.01B | 2.06B | 1.54B | 1.84B | 1.92B | 1.11B | 1.94B | 1.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.36B | 1.95B | 2.26B | 1.90B | 2.18B | 2.34B | 1.91B | 1.89B | 1.98B | 5.23B | 2.00B | 1.71B | 6.93B | 6.04B | 5.31B | 4.42B | 4.16B | 4.60B | 4.37B | 4.10B |
| Other Expenses | -483.84M | 10.33B | 9.03B | 9.63B | 11.29B | 8.93B | 8.76B | 7.20M | 7.16M | 0.00 | 6.54M | 5.27B | -1.61B | -1.13B | -870.56M | -1.06B | -723.33M | -763.15M | -460.81M | -315.63M |
| Operating Expenses | 7.38B | 12.28B | 11.30B | 11.53B | 13.48B | 11.27B | 10.67B | 10.34B | 9.66B | 9.67B | 8.06B | 6.98B | 5.32B | 4.91B | 4.44B | 3.37B | 3.44B | 3.84B | 3.91B | 3.78B |
| Cost & Expenses | 20.94B | 25.13B | 25.79B | 25.48B | 27.45B | 25.72B | 23.95B | 25.16B | 22.99B | 21.92B | 20.35B | 18.55B | 14.51B | 12.79B | 11.47B | 9.92B | 9.81B | 10.16B | 10.30B | 9.82B |
| Interest Income | 678.50M | 698.12M | 717.45M | 1.11B | 762.06M | 772.79M | 525.93M | 721.09M | 1.21B | 1.58B | 1.74B | 1.75B | 1.45B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 17.99M | 18.10M | 19.96M | 35.31M | 63.36M | 5.54M | 1.89M | 2.50M | 4.21M | 0.00 | 3.32M | 3.34M | 3.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 695.36M | 656.23M | 680.42M | 784.61M | 825.34M | 484.47M | 377.33M | 257.11M | 247.77M | 202.82M | 198.81M | 178.39M | 204.08M | 176.28M | 163.69M | 163.37M | 205.37M | 200.76M | 199.83M | 217.24M |
| EBITDA | 8.87B | 9.03B | 8.49B | 5.36B | 3.92B | 7.31B | 5.78B | 5.38B | 6.03B | 5.09B | 7.31B | 8.52B | 9.55B | 8.89B | 7.78B | 7.17B | 6.44B | 5.86B | 5.08B | 4.50B |
| EBITDA Ratio | 25.69% | 27.83% | 25.54% | 26.28% | 19.41% | 22.43% | 19.60% | 16.91% | 21.78% | 19.29% | 27.61% | 37.19% | 48.29% | 42.16% | 40.37% | 34.79% | 31.72% | 25.45% | 20.61% | 27.14% |
| Operating Income | 13.60B | 8.39B | 7.69B | 7.61B | 5.43B | 6.53B | 5.25B | 3.93B | 4.64B | 4.89B | 5.20B | 7.99B | 9.27B | 8.72B | 7.61B | 7.01B | 6.28B | 5.66B | 4.88B | 4.28B |
| Operating Income Ratio | 39.38% | 25.81% | 23.46% | 23.80% | 16.85% | 20.88% | 18.28% | 13.50% | 16.79% | 18.52% | 20.34% | 30.12% | 38.99% | 40.52% | 39.90% | 41.40% | 39.02% | 35.80% | 32.16% | 30.35% |
| Total Other Income/Expenses | -5.44B | -4.03B | -3.79B | -5.02B | -1.74B | 295.59M | 634.72M | 1.19B | 1.17B | -2.83B | 1.92B | 373.08M | -3.23B | 0.00 | -18.50M | -71.50M | -68.00M | -68.00M | -77.78M | 0.00 |
| Income Before Tax | 8.16B | 8.36B | 7.79B | 5.50B | 3.06B | 6.83B | 5.40B | 5.11B | 5.79B | 6.05B | 7.11B | 8.34B | 9.27B | 8.72B | 7.61B | 7.01B | 6.28B | 5.66B | 4.88B | 4.28B |
| Income Before Tax Ratio | 23.63% | 25.72% | 23.77% | 17.21% | 9.48% | 21.82% | 18.80% | 17.58% | 20.97% | 22.91% | 27.85% | 31.43% | 38.99% | 40.52% | 39.90% | 41.40% | 39.02% | 35.80% | 32.16% | 30.35% |
| Income Tax Expense | 2.26B | 2.29B | 3.98B | 1.92B | 2.13B | 2.37B | 1.89B | 1.74B | 2.03B | 2.23B | 2.30B | 2.72B | 3.05B | 2.93B | 2.61B | 2.38B | 2.18B | 1.99B | 1.77B | 1.57B |
| Net Income | 5.90B | 6.11B | 3.81B | 3.58B | 932.05M | 4.45B | 3.51B | 3.37B | 3.77B | 3.81B | 4.82B | 5.62B | 4.29B | 5.61B | 5.08B | 5.91B | 5.48B | 5.51B | 5.07B | 3.38B |
| Net Income Ratio | 17.08% | 18.78% | 11.62% | 11.20% | 2.89% | 14.24% | 12.21% | 11.58% | 13.64% | 14.45% | 18.85% | 21.17% | 18.02% | 26.06% | 26.62% | 34.91% | 34.05% | 34.83% | 33.40% | 23.95% |
| EPS | 34.83 | 36.05 | 22.48 | 21.14 | 5.50 | 26.29 | 20.70 | 19.88 | 22.21 | 22.50 | 28.44 | 33.17 | 25.30 | 33.09 | 29.98 | 34.89 | 32.32 | 32.53 | 29.55 | 19.34 |
| EPS Diluted | 34.83 | 36.05 | 22.48 | 21.14 | 5.50 | 26.29 | 20.70 | 19.88 | 22.21 | 22.50 | 28.44 | 33.17 | 25.30 | 33.09 | 29.98 | 34.89 | 32.32 | 32.53 | 29.55 | 19.34 |
| Weighted Avg Shares Out | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 171.62M | 174.65M |
| Weighted Avg Shares Out (Dil) | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 171.62M | 174.65M |
Source: https://incomestatements.info
Category: Stock Reports